ENTITY
Innovent Biologics Inc

Innovent Biologics Inc (1801 HK)

519
Analysis
Health Care • China
Innovent Biologics, Inc. operates as a biopharmaceutical company. The Company develops, manufactures, and distributes monoclonal antibody drug candidates for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and other diseases. Innovent Biologics serves customers in China.
more
bullish•Adagene Inc
•27 Jan 2021 09:52

Pre-IPO Adagene Inc (ADAG US) - Advanced Technology but Still Take Time for Commercialization

This article analyzed Adagene Inc. in terms of the DPL platform, the core products in theĀ pipeline (ADG106, ADG126 and ADG116), the financial...

Logo
414 Views
Share
•25 Jan 2021 09:52

China Healthcare Weekly (Jan.22)

The article analyzed the new official document for the volume-based purchase,industry viewpoints on China cryogenic storage market and ā€œAI +...

Logo
370 Views
Share
•18 Jan 2021 09:32

China Healthcare Weekly (Jan.15)

This article analyzed the newĀ interim procedures released by NHSA, trend of blood products and biological drug market, and also include company...

Logo
531 Views
Share
bullish•Man Wah Holdings
•14 Jan 2021 20:13

Man Wah Placement - Riding High on Planned Store Expansion

Man Wah Holdings (1999 HK) plans to raise around US$260m to expand manufacturing facilities in China and open new stores. The stock has nearly...

Logo
557 Views
Share
•14 Jan 2021 19:04

Innovent Biologics Placement - Momentum Is Very Strong but past Deals Have Been Mixed

Innovent Biologics Inc (1801 HK) is looking to raise about U$600m to fund its clinical trialsĀ  and product licensing and possible M&A. This will be...

Logo
546 Views
Share
x